Biomedicine
Retatrutide: the population behind 20.8%—and adverse events
Lilly’s detailed TRIUMPH-2 results concern adults with type 2 diabetes and obesity or overweight. Mean loss at 80 weeks was 20.8% with 12 mg versus 4.0% with placebo.
The trial randomized 1,152 participants across three doses and placebo. The weekly drug activates GIP, GLP-1 and glucagon receptors. The highlighted analysis assumes continued intervention without prohibited weight-management treatment; it is not a guaranteed real-world outcome.
At 12 mg, 34.9% lost at least a quarter of their weight, versus 0.8% on placebo. A1C fell 1.5 percentage points from a 7.7% baseline, versus 0.2 points. Weight and glucose control remain separate endpoints.
High-dose diarrhea, nausea and vomiting rates were 33.6%, 28.0% and 15.7%. Adverse-event discontinuation was 7.7%, versus 4.9% on placebo; Lilly describes most events as mild or moderate.
Lilly plans a US filing in early 2027; approval is pending. We read the release and reporting, not the full paper. Comparisons across populations, durations and estimands cannot establish head-to-head superiority.
Sources and further reading
Post and cited sources reviewed in this batch